Advertisement

Endocrine

, Volume 62, Issue 3, pp 576–587 | Cite as

Berberine promotes glucose uptake and inhibits gluconeogenesis by inhibiting deacetylase SIRT3

  • Bingjie Zhang
  • Yida Pan
  • Lei Xu
  • Dehua Tang
  • Robert Gregory Dorfman
  • Qian Zhou
  • Yuyao Yin
  • Yang Li
  • Lixing Zhou
  • Shimin Zhao
  • Xiaoping Zou
  • Lei WangEmail author
  • Mingming ZhangEmail author
Original Article

Abstract

Objective

Many studies have confirmed the glucose-lowering effect of berberine in type 2 diabetes patients. Although the mechanism of action of berberine involves the improvement of insulin sensitivity, its hypoglycemic mechanism remains elusive. Here we show a new mechanism by which berberine antagonizes glucagon signaling and find that SIRT3 is involved in the hypoglycemic effect of berberine.

Methods

Gene knockout and overexpression were used to assess the inhibitory effect of berberine on SIRT3. Downstream signaling pathways and the hypoglycemic effect of SIRT3 were evaluated by immunoblotting and metabolic monitoring.

Results

We found that berberine led to mitochondrial dysfunction and AMP accumulation by inhibiting deacetylase SIRT3. We confirmed that AMP accumulation activated the AMPK signaling pathway and further promoted glucose uptake. Simultaneously, AMP accumulation reduced cyclic AMP (cAMP) levels and abrogated the phosphorylation of critical protein targets of protein kinase A (PKA). Furthermore, we found that phosphoenolpyruvate carboxykinase 1 (PEPCK1) is a key gluconeogenesis enzyme that can be stabilized by glucagon. Berberine caused significant PEPCK1 ubiquitination and degradation by antagonizing glucagon and was accompanied by high levels of PEPCK1 acetylation. Interestingly, berberine-induced glucagon inhibition is independent of AMPK activation. The in vivo data from sirt3 knockout mice were further confirmed by the in vitro experiments.

Conclusions

Berberine promotes glucose uptake and inhibits gluconeogenesis by inhibiting SIRT3, and regulating mitochondria-related pathways may provide a novel approach to the development of antidiabetic drugs.

Keywords

Berberine PEPCK1 AMP Glucose SIRT3 

Notes

Acknowledgements

We thank the Zhao lab for offering their help.

Funding

This work was supported by grants from the National Natural Science Foundation of China (No. 81602076, 81672935 and 81472756), Outstanding Youth Project of Nanjing City (No. JQX17002), the Jiangsu Clinical Medical Center of Digestive Disease (BL2012001), the Natural Science Foundation from the Department of Science & Technology of Jiangsu Province (BK20160113), the Fundamental Research Funds for the Central Universities (No. 021414380244), the Foundation of Jiangsu Provincial Commission of Health and Family Planning (Q201611).

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All applicable international, national, and/or institutional guidelines for the care and use of animals were followed.

Supplementary material

12020_2018_1689_MOESM1_ESM.doc (549 kb)
Supplementary Information

References

  1. 1.
    J.A. Davidson, W.L. Holland, M.G. Roth, Glucagon therapeutics, dawn of a new era for diabetes care. Diabetes Metab. Res. Rev. 32, 660–665 (2016)CrossRefGoogle Scholar
  2. 2.
    Y. Zhu, C. Zhang, Prevalence of gestational diabetes and risk of progression to type 2 diabetes: a global perspective. Curr. Diabetes Rep. 16, 7 (2016)CrossRefGoogle Scholar
  3. 3.
    M. Xu, Y. Xiao, J. Yin et al. Berberine promotes glucose consumption independently of AMP-activated protein kinase activation. PLoS One 9, e103702 (2014)CrossRefGoogle Scholar
  4. 4.
    L. Zhou, Y. Yang, X. Wang et al. Berberine stimulates glucose transport through a mechanism distinct from insulin. Metabolism 56, 405–412 (2007)CrossRefGoogle Scholar
  5. 5.
    W.H. Chueh, J.Y. Lin, Protective effect of berberine on serum glucose levels in non-obese diabetic mice. Int Immunopharmacol. 12, 534–538 (2012)CrossRefGoogle Scholar
  6. 6.
    Q. Zhang, X. Xiao, M. Li et al. Berberine moderates glucose metabolism through the GnRH-GLP-1 and MAPK pathways in the intestine. BMC Complement Altern. Med 14, 188 (2014)CrossRefGoogle Scholar
  7. 7.
    X. Xia, J. Yan, Y. Shen et al. Berberine improves glucose metabolism in diabetic rats by inhibition of hepatic gluconeogenesis. PLoS One 6, e16556 (2011)CrossRefGoogle Scholar
  8. 8.
    J.M. Brusq, N. Ancellin, P. Grondin et al. Inhibition of lipid synthesis through activation of AMP kinase: an additional mechanism for the hypolipidemic effects of berberine. J. Lipid Res 47, 1281–1288 (2006)CrossRefGoogle Scholar
  9. 9.
    Y.S. Lee, W.S. Kim, K.H. Kim et al. Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states. Diabetes 55, 2256–2264 (2006)CrossRefGoogle Scholar
  10. 10.
    W. Chang, M. Zhang, J. Li et al. Berberine improves insulin resistance in cardiomyocytes via activation of 5’-adenosine monophosphate-activated protein kinase. Metabolism 62, 1159–1167 (2013)CrossRefGoogle Scholar
  11. 11.
    J.M. Hwang, C.J. Wang, F.P. Chou et al. Inhibitory effect of berberine on tert-butyl hydroperoxide-induced oxidative damage in rat liver. Arch. Toxicol. 76, 664–670 (2002)CrossRefGoogle Scholar
  12. 12.
    D.A. Sinclair, L. Guarente, Unlocking the secrets of longevity genes. Sci. Am. 294(48-51), 54–47 (2006)Google Scholar
  13. 13.
    J. Couzin-Frankel, Genetics. Aging genes: the sirtuin story unravels. Science 334, 1194–1198 (2011)CrossRefGoogle Scholar
  14. 14.
    R. Raynes, J. Brunquell, S.D. Westerheide, Stress inducibility of SIRT1 and its role in cytoprotection and cancer. Genes Cancer 4, 172–182 (2013)CrossRefGoogle Scholar
  15. 15.
    T. Finkel, C.X. Deng, R. Mostoslavsky, Recent progress in the biology and physiology of sirtuins. Nature 460, 587–591 (2009)CrossRefGoogle Scholar
  16. 16.
    M.D. Hirschey, T. Shimazu, E. Goetzman et al. SIRT3 regulates mitochondrial fatty-acid oxidation by reversible enzyme deacetylation. Nature 464, 121–125 (2010)CrossRefGoogle Scholar
  17. 17.
    A.S. Hebert, K.E. Dittenhafer-Reed, W. Yu, et al. Calorie restriction and SIRT3 trigger global reprogramming of the mitochondrial protein acetylome. Mol. Cell. 49, 186–199 (2012)CrossRefGoogle Scholar
  18. 18.
    S. Shukla, A. Sharma, V.K. Pandey, S. Raisuddin, P. Kakkar, Concurrent acetylation of FoxO1/3a and p53 due to sirtuins inhibition elicit Bim/PUMA mediated mitochondrial dysfunction and apoptosis in berberine-treated HepG2 cells. Toxicol. Appl. Pharmacol. 291, 70–83 (2016)CrossRefGoogle Scholar
  19. 19.
    L.W. Finley, A. Carracedo, J. Lee et al. SIRT3 opposes reprogramming of cancer cell metabolism through HIF1alpha destabilization. Cancer Cell 19, 416–428 (2011)CrossRefGoogle Scholar
  20. 20.
    M.N. Berry, D.S. Friend, High-yield preparation of isolated rat liver parenchymal cells: a biochemical and fine structural study. J. Cell Biol. 43, 506–520 (1969)CrossRefGoogle Scholar
  21. 21.
    D. D’Alessio, The role of dysregulated glucagon secretion in type 2 diabetes. Diabetes Obes. Metab. 13(Suppl 1), 126–132 (2011)CrossRefGoogle Scholar
  22. 22.
    G. Jiang, B.B. Zhang, Glucagon and regulation of glucose metabolism. Am. J. Physiol. Endocrinol. Metab. 284, E671–678 (2003)CrossRefGoogle Scholar
  23. 23.
    R.H. Unger, A.D. Cherrington, Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover. J. Clin. Invest 122, 4–12 (2012)CrossRefGoogle Scholar
  24. 24.
    R.A. Miller, Q. Chu, J. Xie, M. Foretz, B. Viollet, M.J. Birnbaum, Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP. Nature 494, 256–260 (2013)CrossRefGoogle Scholar
  25. 25.
    W. Chang, M. Zhang, L. Chen, G.M. Hatch, Berberine inhibits oxygen consumption rate independent of alteration in cardiolipin levels in H9c2 cells. Lipids 52, 961–967 (2017)CrossRefGoogle Scholar
  26. 26.
    B.H. Ahn, H.S. Kim, S. Song et al. A role for the mitochondrial deacetylase Sirt3 in regulating energy homeostasis. Proc. Natl. Acad. Sci. USA 105, 14447–14452 (2008)CrossRefGoogle Scholar
  27. 27.
    B. Viollet, B. Guigas, J. Leclerc et al. AMP-activated protein kinase in the regulation of hepatic energy metabolism: from physiology to therapeutic perspectives. Acta Physiol. 196, 81–98 (2009)CrossRefGoogle Scholar
  28. 28.
    I.W. Smoak, Glucose metabolism in mouse embryos exposed to metformin in vitro. Toxicol. Vitr. 13, 27–33 (1999)CrossRefGoogle Scholar
  29. 29.
    O. Warburg, On the origin of cancer cells. Science 123, 309–314 (1956)CrossRefGoogle Scholar
  30. 30.
    D.K. Granner, R.M. O’Brien, Molecular physiology and genetics of NIDDM. Importance of metabolic staging. Diabetes Care 15, 369–395 (1992)CrossRefGoogle Scholar
  31. 31.
    H. Matsuoka, A. Shima, D. Kuramoto, D. Kikumoto, T. Matsui, A. Michihara, Phosphoenolpyruvate carboxykinase, a key enzyme that controls blood glucose, is a target of retinoic acid receptor-related orphan receptor alpha. PLoS One 10, e0137955 (2015)CrossRefGoogle Scholar
  32. 32.
    R.W. Hanson, Y.M. Patel, Phosphoenolpyruvate carboxykinase (GTP): the gene and the enzyme. Adv. Enzymol. Relat. Areas Mol. Biol. 69, 203–281 (1994)PubMedGoogle Scholar
  33. 33.
    C.K. Nye, R.W. Hanson, S.C. Kalhan, Glyceroneogenesis is the dominant pathway for triglyceride glycerol synthesis in vivo in the rat. J. Biol. Chem. 283, 27565–27574 (2008)CrossRefGoogle Scholar
  34. 34.
    R.L. Tannen, Ammonia metabolism. Am. J. Physiol. 235, F265–277 (1978)PubMedGoogle Scholar
  35. 35.
    K. Chakravarty, H. Cassuto, L. Reshef, R.W. Hanson, Factors that control the tissue-specific transcription of the gene for phosphoenolpyruvate carboxykinase-C. Crit. Rev. Biochem Mol. 40, 129–154 (2005)CrossRefGoogle Scholar
  36. 36.
    S. Zhao, W. Xu, W. Jiang et al. Regulation of cellular metabolism by protein lysine acetylation. Science 327, 1000–1004 (2010)CrossRefGoogle Scholar
  37. 37.
    M.Y. Wang, H. Yan, Z. Shi et al. Glucagon receptor antibody completely suppresses type 1 diabetes phenotype without insulin by disrupting a novel diabetogenic pathway. Proc. Natl. Acad. Sci. USA 112, 2503–2508 (2015)CrossRefGoogle Scholar
  38. 38.
    D.B. Lombard, F.W. Alt, H.L. Cheng et al. Mammalian Sir2 homolog SIRT3 regulates global mitochondrial lysine acetylation. Mol. Cell Biol. 27, 8807–8814 (2007)CrossRefGoogle Scholar
  39. 39.
    J.S. Teodoro, F.V. Duarte, A.P. Gomes et al. Berberine reverts hepatic mitochondrial dysfunction in high-fat fed rats: a possible role for SirT3 activation. Mitochondrion 13, 637–646 (2013)CrossRefGoogle Scholar
  40. 40.
    R.L. Rodgers, Glucagon and cyclic AMP: time to turn the page? Curr. Diabetes Rev. 8, 362–381 (2012)CrossRefGoogle Scholar
  41. 41.
    G. Bobe, J.C. Velez, D.C. Beitz, S.S. Donkin, Glucagon increases hepatic mRNA concentrations of ureagenic and gluconeogenic enzymes in early-lactation dairy cows. J. Dairy Sci. 92, 5092–5099 (2009)CrossRefGoogle Scholar
  42. 42.
    M.J. Hill, S. Suzuki, J.H. Segars, T. Kino, CRTC2 Is a coactivator of GR and couples GR and CREB in the regulation of hepatic gluconeogenesis. Mol. Endocrinol. 30, 104–117 (2016)CrossRefGoogle Scholar
  43. 43.
    Y.Y. Lin, J.Y. Lu, J.M. Zhang et al. Protein acetylation microarray reveals that NuA4 controls key metabolic target regulating gluconeogenesis. Cell 136, 1073–1084 (2009)CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Bingjie Zhang
    • 1
    • 2
  • Yida Pan
    • 3
  • Lei Xu
    • 1
  • Dehua Tang
    • 1
  • Robert Gregory Dorfman
    • 4
  • Qian Zhou
    • 5
  • Yuyao Yin
    • 1
  • Yang Li
    • 1
  • Lixing Zhou
    • 1
  • Shimin Zhao
    • 5
    • 6
  • Xiaoping Zou
    • 1
  • Lei Wang
    • 1
    Email author
  • Mingming Zhang
    • 1
    • 5
    • 6
    Email author
  1. 1.Department of Gastroenterology, Drum Tower hospital affiliated to Nanjing University Medical SchoolNanjing UniversityNanjingChina
  2. 2.Department of Endocrinology, Drum Tower hospital affiliated to Nanjing University Medical SchoolNanjing UniversityNanjingChina
  3. 3.Department of Digestive Diseases of Huashan HospitalFudan UniversityShanghaiChina
  4. 4.Northwestern University Feinberg School of MedicineChicagoUSA
  5. 5.School of Life SciencesFudan UniversityShanghaiChina
  6. 6.Key laboratory of Reproduction Regulation of NPFPC (SIPPR, IRD)Fudan UniversityShanghaiChina

Personalised recommendations